Associated Papers
Outcomes for Patients With SPOP Mutated Castration-Resistant Prostate Cancer (CRPC) Treated With an Androgen Receptor Pathway Inhibitor (ARPI).
Park JJ et al.
Clinical Genitourinary Cancer, 2026
Circulating Tumor DNA as a Biomarker for Precision Medicine in Prostate Cancer: A Systematic Review.
Chanhih N et al.
International Journal of Molecular Sciences, 2025
Clinical implications of AR alterations in advanced prostate cancer: a multi-institutional collaboration.
Zengin ZB et al.
Prostate Cancer and Prostatic Diseases, 2025
An Autophagy-Targeting Chimera Induces Degradation of Androgen Receptor Mutants and AR-v7 in Castration-Resistant Prostate Cancer.
Bae TH et al.
Cancer Research, 2025
Comparison of androgen receptor mutation detection between plasma extracellular vesicle DNA and cell-free DNA and its relationship to prostate cancer prognosis.
Ding T et al.
Annals of Medicine, 2024
Structural perspectives on the androgen receptor, the elusive shape-shifter.
Johnson MJ et al.
Steroids, 2024
Clinical implications of AR alterations in advanced prostate cancer: A multi-institutional collaboration.
Dorff T et al.
Research Square, 2023
Androgen receptor mutations modulate activation by 11-oxygenated androgens and glucocorticoids.
Snaterse G et al.
Prostate Cancer and Prostatic Diseases, 2023
A partially open conformation of an androgen receptor ligand-binding domain with drug-resistance mutations.
Doamekpor SK et al.
Acta Crystallographica. Section F, Structural Biology Communications, 2023
Simulating androgen receptor selection in designer yeast.
Zhang H et al.
Synthetic and Systems Biotechnology, 2022
Androgen receptor mutations for precision medicine in prostate cancer.
Shiota M et al.
Endocrine-related Cancer, 2022
Structural and molecular insights into the mechanism of resistance to enzalutamide by the clinical mutants in androgen receptor (AR) in castration-resistant prostate cancer (CRPC) patients.
Khan A et al.
International Journal of Biological Macromolecules, 2022
Androgen Receptor Signaling in Prostate Cancer and Therapeutic Strategies.
Jacob A et al.
Cancers, 2021
The somatic molecular evolution of cancer: Mutation, selection, and epistasis.
Dasari K et al.
Progress in Biophysics and Molecular Biology, 2021
Spirocyclic Thiohydantoin Antagonists of F877L and Wild-Type Androgen Receptor for Castration-Resistant Prostate Cancer.
Zhang Z et al.
Acs Medicinal Chemistry Letters, 2021
Evaluation of Darolutamide (ODM201) Efficiency on Androgen Receptor Mutants Reported to Date in Prostate Cancer Patients.
Lallous N et al.
Cancers, 2021
Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms.
Tukachinsky H et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2021
Duality of glucocorticoid action in cancer: tumor-suppressor or oncogene?
Mayayo-Peralta I et al.
Endocrine-related Cancer, 2021
Androgen receptor (AR) antagonism triggers acute succinate-mediated adaptive responses to reactivate AR signaling.
Saxena N et al.
Embo Molecular Medicine, 2021
Multi-omics integration identifies key upstream regulators of pathomechanisms in hypertrophic cardiomyopathy due to truncating MYBPC3 mutations.
Pei J et al.
Clinical Epigenetics, 2021
Loss of CHD1 Promotes Heterogeneous Mechanisms of Resistance to AR-Targeted Therapy via Chromatin Dysregulation.
Zhang Z et al.
Cancer Cell, 2020
Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells.
Hamid AB et al.
Cancers, 2020
Comprehensive Analysis of AR Alterations in Circulating Tumor DNA from Patients with Advanced Prostate Cancer.
Ledet EM et al.
The Oncologist, 2020
Towards precision oncology in advanced prostate cancer.
Ku SY et al.
Nature Reviews. Urology, 2019
Detecting predictive androgen receptor modifications in circulating prostate cancer cells.
Steinestel J et al.
Oncotarget, 2019
Clinical utility of androgen receptor gene aberrations in circulating cell-free DNA as a biomarker for treatment of castration-resistant prostate cancer.
Sumiyoshi T et al.
Scientific Reports, 2019
p53 status in the primary tumor predicts efficacy of subsequent abiraterone and enzalutamide in castration-resistant prostate cancer.
Maughan BL et al.
Prostate Cancer and Prostatic Diseases, 2018
Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
Borgmann H et al.
European Urology, 2018
Clinical relevance of androgen receptor alterations in prostate cancer.
Jernberg E et al.
Endocrine Connections, 2017
Detection fidelity of AR mutations in plasma derived cell-free DNA.
Goldstein A et al.
Oncotarget, 2017
A novel nonsense mutation in androgen receptor confers resistance to CYP17 inhibitor treatment in prostate cancer.
Han D et al.
Oncotarget, 2017
Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer.
Wyatt AW et al.
Jama Oncology, 2016
The Effect of F877L and T878A Mutations on Androgen Receptor Response to Enzalutamide.
Prekovic S et al.
Molecular Cancer Therapeutics, 2016
Novel mechanism-based therapeutics for androgen axis blockade in castration-resistant prostate cancer.
Teply BA et al.
Current Opinion in Endocrinology, Diabetes, and Obesity, 2016
Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients.
Lallous N et al.
Genome Biology, 2016